Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Medulloblastoma
A study if the safety and effectiveness of nifurtimox in children with neuroblastoma or medulloblastoma, that has returned or is not responding to treatment.
Ages 0-21 years at the time of diagnosis. Diagnosis of neuroblastoma or medulloblastoma. Disease has not responded to previous treatment. Disease is measurable bu accepted tests.
Exclusion Criteria:
Patients who weigh less than 3.5 kg (7.7 lbs). Currently receiving another study drug. Currently receiving other anticancer agents.